ACM
KALV

Aster Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Aster Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-278
Closed -$4.49K – 1096
2025
Q4 		$4.49K Buy
+278
New +$3.68K ﹤0.01% 883

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aster Capital Management's KALV Position: Q1 2026 in Review

Aster Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 278 shares — an estimated $4.49K sold.

Aster Capital Management first reported a position in KALV in Q4 2025 and held it in 1 quarter. The position peaked at $4.49K in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Aster Capital Management reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 278 KalVista Pharmaceuticals shares in Q1 2026, an estimated $4.49K.
  • Aster Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Aster Capital Management's KalVista Pharmaceuticals position peaked at $4.49K in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.